SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announces the initiation of a Phase 2 clinical trial with the Company’s glucagon receptor antagonist LGD-6972 for the ...
1 Day 6972 -0.18% DJIA 0.10% Russell 2K 1.18% Retail/Wholesale 0.99% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results